Company intelligence / Profile preview
Castle Creek Biosciences
Exton, Pennsylvania, United Statescastlecreekbio.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Castle Creek Biosciences is conducting a registrational Phase 3 clinical trial of its lead candidate, D-Fi (dabocemagene autoficel/FCX-007), for patients with dystrophic epidermolysis bullosa (DEB)[2][6]. The company is also evaluating FCX-013 in a Phase 1/2 clinical trial for the treatment of moderate to severe localized scleroderma[6][9].
- Therapeutic areas
- Rare DiseasesDermatologyMetabolic DisordersRheumatology
- Modalities
- Gene therapyCell therapy
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
03
Partnerships
Mayo Clinic
Beyond the preview
Go deeper on Castle Creek Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Castle Creek Biosciences.